The impact of the COVID-19 pandemic on ADHD medicine consumption in 47 countries and regions.

Gimbach S, Vogel D, Fried R, Faraone SV, Banaschewski T, Buitelaar J, Döpfner M, Ammer R

Open source

DOI
10.1016/j.euroneuro.2023.04.008
Published
2023 Aug
Container
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.euroneuro.2023.04.008,
  title = {The impact of the COVID-19 pandemic on ADHD medicine consumption in 47 countries and regions.},
  author = {Gimbach S and Vogel D and Fried R and Faraone SV and Banaschewski T and Buitelaar J and Döpfner M and Ammer R},
  year = {2023},
  journal = {European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology},
  doi = {10.1016/j.euroneuro.2023.04.008},
  url = {https://doi.org/10.1016/j.euroneuro.2023.04.008}
}

RIS

TY  - JOUR
TI  - The impact of the COVID-19 pandemic on ADHD medicine consumption in 47 countries and regions.
AU  - Gimbach S
AU  - Vogel D
AU  - Fried R
AU  - Faraone SV
AU  - Banaschewski T
AU  - Buitelaar J
AU  - Döpfner M
AU  - Ammer R
PY  - 2023
JO  - European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
DO  - 10.1016/j.euroneuro.2023.04.008
UR  - https://doi.org/10.1016/j.euroneuro.2023.04.008
ER  - 

APA

S, G., D, V., R, F., SV, F., T, B., J, B., M, D., & R, A. (2023). The impact of the COVID-19 pandemic on ADHD medicine consumption in 47 countries and regions.. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2023.04.008

Source records